{"links":{"feed":"https://www.erudio.com/reports/morpheus-panbc-nct03424005/feed.json","html":"https://www.erudio.com/reports/morpheus-panbc-nct03424005","json":"https://www.erudio.com/reports/morpheus-panbc-nct03424005.json","markdown":"https://www.erudio.com/reports/morpheus-panbc-nct03424005.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"morpheus-panbc-nct03424005"}},"request":"https://www.erudio.com/contact?report=morpheus-panbc-nct03424005"},"offer":{"cited_clinicians":0,"cited_commentary_sources":4,"verified_hcp_statements":7,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=morpheus-panbc-nct03424005","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=morpheus-panbc-nct03424005","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/morpheus-panbc-nct03424005","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 7 verified statements · none from confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T14:55:44.244515Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Objective Response Rate (ORR)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Presentation salience and brief favorable reactions"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Future pembrolizumab data and possible practice change"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":1,"cited_clinicians":0,"cited_clinicians_by_role":{},"cited_physicians":0,"cited_sources":4,"claims_by_expression_type":{"comparison":1,"interpretation":3,"opinion":3},"claims_by_kind":{"source_observation":7},"clinician_statements":0,"evidence_units":5,"findings":3,"people_cited":5,"people_identity_verified":4,"people_total":5,"screened_sources":12,"verified_claims":7},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":4},"limitations":2,"links":{"context":1,"support":4},"ma_question":true,"named_voices":4,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"MORPHEUS: speakers note activity; one flags small n, immature survival","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-89be6e9f5f780f86ab3a"],"clause":"one flags small n, immature survival","holders":1},"cited_claim_ids":["claim-89be6e9f5f780f86ab3a","claim-cfa8ce7840aea8910e89","claim-32b1fc4f05128f663df5","claim-0b2dd4f64592028fd178"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"4 statements from 4 speakers in 3 sources","holder_line":"4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “one flags small n, immature survival”"},{"cited_clinicians":0,"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":1,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"MORPHEUS: a speaker relays apparent benefit but flags short follow-up","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-fcf2efd9334557488acb"],"clause":"flag short follow-up","holders":1},"cited_claim_ids":["claim-4918ddf7f9333e19e350","claim-fcf2efd9334557488acb"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view; 1 of them holds its caveat, “flag short follow-up”"},{"cited_clinicians":0,"id":"F3","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Pembrolizumab: a speaker looks ahead to data and possible practice change","title_holders":{"cited_claim_ids":["claim-06a52baa0a6f27a34c61"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"How do X accounts interpret activity, and what interim-evidence limits does one emphasize?"},{"id":"section-2","level":2,"title":"One interview relayed apparent comparative benefit while retaining the short-follow-up caveat"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One X account anticipated possible practice change and looked ahead to pembrolizumab data"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T14:55:44.244515Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T15:04:02Z","record_hash":"fe4e80afaaa8ead31f3e5560bb8d8b5c50a84c8f75884f020f85bb482d91a971","release_hash":"61b5095726d401d7aa480bfe00afea217559ef121cea566f92cb746e12df277c","report_id":"erudio-nct03424005","run_id":"bf718b51-6abf-4f40-8917-4240e3828222","schema_version":"5.0","slug":"morpheus-panbc-nct03424005","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Speakers viewed MORPHEUS-panBC favorably for early activity, although one cautioned that the interim patient group was small and survival data were not yet mature. One speaker looked ahead to pembrolizumab data and a possible change in practice. The statements provide no safety interpretation or evidence that routine care changed.","examples":[],"meta_description":"12 sources screened · 7 verified statements (0 from clinicians verified by NPI or staff page) from 4 sources · 3 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T15:04:02Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":12},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","7 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 51 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion; reposts do not add independent clinical assessments.","Searches emphasized trial identifiers and names, so discussion using unnamed references or other variants may be missing.","The favorable interpretations were qualified by a small interim patient group, immature survival and short follow-up; they should not be read as mature benefit–risk conclusions.","No numerical comparative endpoint estimates, safety or tolerability interpretation, or documented change in routine care appears in the cited statements.","No protocol was listed in the registry, and no publication for the exact trial was identified for this edition. This report describes public interpretations rather than an independent assessment of a full trial report."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":4},"count":4,"evidence_window":{"end":"2024-05-20","start":"2024-05-15"},"retrieval_snapshot":"2026-11-20T11:49:01.540375Z","timeline":[{"count":3,"week":"2024-W20"},{"count":1,"week":"2024-W21"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT03424005:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03424005:context","quote_policy":"short_quote_link_out"},{"id":"openfda:0b59e98c-5b34-4b93-90f6-20526f4d4f88:20260721","quote_policy":"short_quote_link_out"},{"id":"openfda:a617b089-ce66-464b-987b-b45d029b4d6f:20261013","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1656678427037138953:9b7db646-9c88-44d1-9981-ce282a07da3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790764174898839881:9dd32070-aa1b-40c2-a44b-f0a29a2e858b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790764213922623814:d228996d-66b7-496f-9450-9fc2613e3f7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790788670657536409:89f982c0-59ce-402f-ad42-3566228ce431","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790841693018730865:03955dcd-5a97-4dcc-b90f-84ec43d5be4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790992418507993286:985cf005-d7bd-47e9-b910-dd06606c5d21","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1792236462265512273:37f32c8a-7a00-41e1-a322-e2c1eb7fc425","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1816656027569340885:0f1b7f77-4872-479e-a4db-1d570ca6ab88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929621312793690366:ed883927-e27b-45b1-b8ab-7f3dca2ec5af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1943293146063867980:da410688-dac1-4999-92f7-61c43e7a87c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114373107154931882:c788069a-bc8c-4c6c-b3c4-08fcc8ddfc98","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:XnnEkjIJgZM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":11,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-10-25","start":"2023-05-11"},"retrieval_snapshot":"2026-11-20T11:49:01.540375Z","timeline":[{"count":1,"week":"2023-W19"},{"count":6,"week":"2024-W20"},{"count":1,"week":"2024-W21"},{"count":1,"week":"2024-W30"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":2}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"},{"brand_names":["Tecentriq"],"label":"atezolizumab","slug":"atezolizumab"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"ipatasertib","slug":"ipatasertib"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"ladiratuzumab vedotin","slug":"ladiratuzumab-vedotin"},{"brand_names":["Avastin"],"label":"bevacizumab","slug":"bevacizumab"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"selicrelumab","slug":"selicrelumab"},{"brand_names":["Actemra","Actemra Actpen","Avtozma","Tofidence","Tyenne"],"label":"tocilizumab","slug":"tocilizumab"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"},{"brand_names":["Trodelvy"],"label":"sacituzumab govitecan","slug":"sacituzumab-govitecan"},{"brand_names":["Verzenio"],"label":"abemaciclib","slug":"abemaciclib"},{"brand_names":["Faslodex"],"label":"fulvestrant","slug":"fulvestrant"},{"brand_names":["Kisqali"],"label":"ribociclib","slug":"ribociclib"},{"brand_names":["Itovebi"],"label":"inavolisib","slug":"inavolisib"},{"brand_names":["Enhertu"],"label":"trastuzumab deruxtecan","slug":"trastuzumab-deruxtecan"},{"brand_names":["Femara"],"label":"letrozole","slug":"letrozole"},{"brand_names":["Jardiance"],"label":"empagliflozin","slug":"empagliflozin"},{"brand_names":["Ibrance"],"label":"palbociclib","slug":"palbociclib"},{"brand_names":["Fortamet","Glucophage","Glucophage Xr","Glumetza","Metformin Hydrochloride Er","Metformin Hydrochloride Extended-Release","Riomet","Riomet Er"],"label":"metformin","slug":"metformin"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"atirmociclib","slug":"atirmociclib"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"giredestrant","slug":"giredestrant"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"MORPHEUS-panBC","aliases":["MORPHEUS-panBC","Morpheus-panBC","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)"],"brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","collaborators":["Gilead Sciences","Pfizer"],"conditions":["Metastatic Breast Cancer"],"display_condition":"metastatic breast cancer","display_interventions":[["atezolizumab","tocilizumab"],["atezolizumab","sacituzumab govitecan"],["atezolizumab","ipatasertib"]],"enrollment":{"count":1132,"type":"ESTIMATED"},"interventions":[{"name":"Capecitabine","synonyms":["RO0091978"],"type":"DRUG"},{"name":"Atezolizumab","synonyms":["RO5541267"],"type":"DRUG"},{"name":"Ipatasertib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"SGN-LIV1A","synonyms":["RO7235441, Ladiratuzumab vedotin"],"type":"DRUG"},{"name":"Bevacizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Chemotherapy (Gemcitabine + Carboplatin or Eribulin)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Selicrelumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Tocilizumab","synonyms":["RO4877533"],"type":"DRUG"},{"name":"Nab-Paclitaxel","synonyms":["RO0247506"],"type":"DRUG"},{"name":"Sacituzumab Govitecan","synonyms":["RO7445735"],"type":"DRUG"},{"name":"Abemaciclib","synonyms":["RO7071651"],"type":"DRUG"},{"name":"Fulvestrant","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ribociclib (Dose #1)","synonyms":["RO7072612"],"type":"DRUG"},{"name":"Inavolisib (Dose #1)","synonyms":["GDC-0077, RO7113755"],"type":"DRUG"},{"name":"Trastuzumab Deruxtecan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Ribociclib (Dose #2)","synonyms":["RO7072612"],"type":"DRUG"},{"name":"Letrozole","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Inavolisib (Dose #2)","synonyms":["GDC-0077, RO7113755"],"type":"DRUG"},{"name":"Empagliflozin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Palbociclib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Metformin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Atirmociclib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Giredestrant","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT03424005","official_title":"A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2030-09-30","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Baseline until disease progression or loss of clinical benefit (up to approximately 12 years)"}],"registered_date":{"date":"2018-02-06","type":"ACTUAL"},"registry_last_updated":"2026-11-06","registry_url":"https://clinicaltrials.gov/study/NCT03424005","short_name":"MORPHEUS-panBC","short_name_basis":"canonical_name","sponsor":"Hoffmann-La Roche","start_date":{"date":"2018-03-30","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase1, phase2","study_ids":[{"id":"CO40115","type":"sponsor_study_id"},{"id":"2017-002038-21","type":"eudract_number"},{"id":"2023-503629-20-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}